System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Olivier Dubreuil

Oncology — Groupe Hospitalier Diaconesses Croix Saint-Simon, France

LeadR Profile

Olivier Dubreuil Groupe Hospitalier Diaconesses Croix Saint-Simon France
969 ScienceLeadR Reputation 969

Unlock

Register Login
Network Map

Oncology

Subspecialties: Cardiology - Public Health - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Groupe Hospitalier Diaconesses Croix Saint-Simon

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 134

Citations

Citations: 5 136 1st author: 4 Last author: 0 Unique author: 0

Main journals

Ann Oncol 11
Dig Liver Dis 11
J Clin Oncol 11
Eur J Cancer 7
Clin Res Hepatol Gastroenterol 6

Best Journals

Ann Oncol 8
N Engl J Med 4
J Clin Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary study.
cells, disease-free survival, progression-free survival, adenocarcinoma, cell-free nucleic acids, dna, irinotecan		NPJ Precis Oncol20260
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France).
pancreatic neoplasms, paclitaxel, neoplasms, adenocarcinoma, biomarkers, fluorouracil, therapeutics		EClinicalMedicine20260
Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.
dihydrouracil dehydrogenase (nadp), oxidoreductases, phenotype, therapeutics		Dig Liver Dis20260
Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP).
neoplasms, drug therapy, biomarkers, neoplasm metastasis, diagnosis, therapeutics, stomach neoplasms, trastuzumab, chemotherapy		Eur J Cancer20261
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO.
retrospective studies, neoplasms, adenocarcinoma, therapeutics		Eur J Cancer20260

Clinical Studies 49

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 3 21
Phase 2 19
N/A 9

By status:

Recruiting 24
Completed 12
Active not recruiting 7
Not yet recruiting 3
Terminated 2
Unknown 1

By type:

Interventional 44
Observational 5

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 0
multicentric5to9 1
multicentricup10 42

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Rituximab in patients with ST elevation myocardial infarction A phase 2 placebo controlled randomized clinical trial
2022-501893-21-00 — myocardial infarction, st elevation myocardial infarction, rituximab		Phase 2Recruiting2022
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
2024-519875-24-00 — safety, neoplasms, neuroendocrine tumors, carcinoid tumor		Phase 3Not yet recruiting2025
A Randomized Active Controlled Double blind Multicenter Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First line Treatment of Metastatic Colorectal Cancer (HARMONi GI3)
2025-521587-35-00 — neoplasms, bevacizumab, response evaluation criteria in solid tumors, therapeutics, colorectal neoplasms		Phase 3Recruiting2026
DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction
2024-511882-13-01 — myocardial infarction, heart failure, echocardiography, therapeutics		Phase 3Active not recruiting2024
ENGIC 06 (PRODIGE 114) FFCD 2401 FRUQUITAS Randomized phase III trial to compare trifluridine tipiracil Fruquintinib versus trifluridine tipiracil alone for metastatic oeso gastric adenocarcinoma
2025-522395-92-00 — trifluridine, adenocarcinoma		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS